Lilly’s selpercatinib gets FDA priority review for lung and thyroid cancers

This article was originally published here

The company, through its new drug application (NDA), has been seeking FDA approval for selpercatinib for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET

The post Lilly’s selpercatinib gets FDA priority review for lung and thyroid cancers appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply